Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Abiomed has announced the appointment of Charles Simonton to the role of chief medical officer. Simonton was most recently the chief medical officer at Abbott Vascular.
Laurent Fischer will now lead Adverum Biotechnologies as the company’s CEO. Prior to joining Adverum, Fischer was senior vice president and head of the liver therapeutic area at Allergan.
Akcea Therapeutics named Kia Motesharei senior vice president of business development and corporate strategy. Motesharei was most recently the vice president and global head of licensing and business development for neurology and immunology at Merck.
Former Eli Lilly medical director Jim Malone has been named chief medical officer of Bigfoot Biomedical.
Reina Benabou has been named chief development officer at BioXcel Therapeutics. Prior to this new role, Benabou was head of global medical product evaluation at Pfizer.
Thomas Loewald is the new CEO of Cambrex. Previously, Loewald served as president of the flexibles division of ProAmpac.
Susanne Lagerlund has been recruited by Cantargia to assume the role of vice president of regulatory affairs. Most recently, Lagerlund was director of R&D integration at LEO Pharma. Peter Madsen, former chemistry, manufacturing and controls (CMC) biologics project director at Lundbeck, has been appointed by Cantargia to the position of vice president of CMC.
Charles Democko has been named senior vice president of regulatory affairs at Catalyst Biosciences. Most recently, Democko served as the lead for CytomX’s regulatory affairs and quality.
Chimerix has appointed Allen Melemed to the role of chief medical officer. Formerly, Melemed served as distinguished medical fellow and senior director of regulatory affairs oncology of North America at Eli Lilly.
Mental healthcare company COMPASS Pathways has appointed Trevor Mill to the role of chief development officer. Mill was most recently senior vice president of global safety and regulatory sciences at Biogen.
Julia Berretta, current CEO of Genespire, has been appointed CEO of Milan-based startup Epsilen Bio.
Thane Wettig has been appointed chief commercial officer of FibroGen. Wettig was most recently chief commercial officer and metabolic franchise head at Intarcia Therapeutics.
Meri Williams has been named chief technology officer of Healx. Williams was chief technology officer at Monzo prior to this appointment.
Hiroyuki Sonoda, former corporate officer executive director and research planning at JCR Pharmaceuticals, has assumed the roles of senior executive director and head of research and development division, executive director of research division and director of drug discovery research.
Martha Manning has been named vice president, general counsel and secretary at Marinus Pharmaceuticals. Before this role, Manning was executive vice president, general counsel and secretary at Achillion.
Medartis has named Mareike Loch vice president of Europe, Middle East & Africa (EMEA). Loch was formerly vice president EMEA for the trauma, extremities, foot and ankle, sports medicine and biologics business units at Zimmer Biomet.
Lee Rauch, former executive in residence at Columbia Technology Ventures, has been appointed chief operating officer of miRagen Therapeutics.
Navpaul Singh has been hired by Nascent Biotech to be chief medical consultant in charge of research of viral infections, including COVID-19.
Robert Radie, who most recently served as CEO at Zyla Life Sciences, has been appointed CEO of Neuraptive Therapeutics.
Filip Dubovsky has joined Novavax as its chief medical officer. Prior to this appointment, Dubovsky was head of clinical engagement and policy and chief medical officer for clinical affairs at AstraZeneca.
Jackie Schumacher has been appointed to lead regulatory affairs at biopharmaceutical company Rallybio. Previously, Schumacher was vice president of regulatory and quality at Lyndra Therapeutics.
The role of interim head of research at Sangamo Therapeutics will be assumed by Jason Fontenot, who had been the company’s senior vice president of cell therapy.
Marie-Louise Fjällskog has been named chief medical officer at Sensei Biotherapeutics. Fjällskog was most recently vice president of clinical development at Merus.
Paul Overton has been named senior vice president of business development at Sygnature Discovery, a UK-based drug discovery CRO. Most recently, Overton was head of European sales, marketing and key account management at Eurofins.
Andrei Floroiu will now lead Vaxart as its CEO. Floroiu was most recently an executive at Agenus.
Renato Skerlj has been named chief scientific officer of X4 Pharmaceuticals. Prior to this role, Skerlj was senior vice president of research and development at X4.
Alexander Gaidamaka will now serve as senior vice president of technology, manufacturing and quality at XyloCor Therapeutics. Previously, Gaidamaka was vice president of CMC at AmpliPhi Biosciences.
Frank Sanders will be named U.S. president of peptide-based medicine biotech of Zealand Pharma, a role that will go into effect July 6. Sanders was previously the general manager of the U.S. commercial team at Sage Therapeutics.
Zomedica Pharmaceuticals has appointed Robert Cohen to the role of interim CEO. Prior to this appointment, Cohen was president and CEO of EmboMedics.